Airbus Tests Valkyrie Combat Drone in Europe for Eurofighter Integration 
Wall Street Ends Mixed as Investors Await CPI and Bank Earnings 
Hong Kong’s Second Solana ETF Launches With Lower Fees 
PepsiCo Slashes Poppi Earnout Valuation as Growth Slows 
Trump Secures Russian Diesel Deal as US Fuel Prices Surge 
IMF Maintains 2027 Global Growth Forecast at 3.4% Amid Rising Risks 
TSMC Profit Set to Surge 65% as AI Chip Demand Drives Record Earnings 
Asian Stocks Plunge as AI Chip Selloff Hits South Korea and Japan 
Ethereum Foundation-Linked Wallets Move $11.13M in ETH to Kraken 
Global Stocks Mixed as Oil Falls Ahead of US Earnings 
European Auto Stocks Rise as EU-China Trade Deal Targets Hybrid Imports 
Nasdaq Falls as Oil Prices Surge Ahead of Bank Earnings 
Russia Approves Sberbank for Crypto Exchange Services 
Gold Prices Rebound as Dollar Weakens Ahead of US Inflation Data 
Samsung, SK Hynix Shares Fall as China's CXMT Advances DRAM Technology 
Syndax Stock Drops 15% After Axatilimab Trial Failure 
Visa Wins China Approval to Prepare Domestic Payments Expansion 
Add as a preferred source on Google
Samsung Biologics signed a contract manufacturing organization (CMO) deal with GreenLight Biosciences to produce COVID-19 vaccines for poor nations, particularly in Africa. The South Korean pharma company revealed its new partnership agreement with the Boston-based biotech firm on Thursday, Nov. 25.
Samsung Biologics and GreenLight Biosciences’ goal is to bring vaccines to everyone as they want to have a world that has the ability to produce sufficient messenger RNA vaccine doses for billions of people per year.
As per The Korea Herald, the agreement between the companies stated that the Korean pharma company would produce drug materials for GreenLight’s COVID-19 vaccine candidate. The two firms also agreed to scale up research and manufacturing efforts so they can be able to allocate more coronavirus vaccines for underdeveloped countries.
Samsung’s pharma unit added that it would be expanding its production plant in Songdo, Incheon, by building new facilities on the site. The constructions are expected to be completed by April next year.
“We are delighted to partner with GreenLight to leverage our expertise in manufacturing a messenger RNA COVID-19 vaccine candidate to better serve patients in lower income countries,” Samsung Biologics chief executive officer, John Rim, said in a press release. “This collaboration demonstrates a major milestone for Samsung Biologics as we will commence our expanded capabilities and operations to provide one-stop end-to-end messenger RNA production from Drug Substance (DS) to Aseptic Fill Finish (DP) to commercial release, all from a single site.”
Meanwhile, GreenLight Biosciences is also reported to be in the last stage of finalizing its partnership deal with a local partner in Africa. This is a separate agreement with Samsung Biologics, and after the contracts are sealed, the American biotech company is planning to start the phase 1 clinical trials for its vaccine candidate as early as the first quarter of 2022, as per Korea Joongang Daily.
Samsung Biologics and GreenLight Biosciences are producing COVID-19 vaccines using mRNA or messenger ribonucleic acid. This is the same type applied to Pfizer and Moderna vaccines.
Finally, Andrey Zarur, GreenLight CEO, said they are happy to join forces with Samsung to make messenger RNA for their Covid vaccine trial as there is an urgent need to develop vaccines for the whole world.
